---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-123289"
form_type: "8-K"
ticker: "DSGN"
cik: "0001807120"
company_name: "Design Therapeutics, Inc."
filed_at: "2024-11-07T23:59:59+00:00"
generated_at: "2026-05-30T03:45:17.806010+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Design Therapeutics Q3 net loss $13.0M; FECD Phase 1 trial initiated, data H1 2025

## Summary
- Net loss of $13.0M for Q3 2024; R&D expense $11.9M, G&A expense $4.4M.
- Cash and securities $254.1M as of Sep 30, 2024; expected to fund operations into 2029.
- FECD DT-168 Phase 1 trial initiated in healthy volunteers; initial data expected H1 2025.
- FA DT-216P2 Phase 1 single ascending dose study in healthy volunteers on track for H1 2025.
- Preclinical programs advancing toward development candidate selection in HD and DM1.

## SEC filing metadata
- accession: 0000950170-24-123289
- form_type: 8-K
- ticker: DSGN
- cik: 0001807120
- company_name: Design Therapeutics, Inc.
- filed_at: 2024-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1807120/000095017024123289/0000950170-24-123289-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1807120/000095017024123289/dsgn-20241107.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-123289
- JSON: https://secwatch.observer/filing/0000950170-24-123289.json
- Plain text: https://secwatch.observer/filing/0000950170-24-123289.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.